Symbols / INO
INO Chart
About
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the University of Pennsylvania, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 130.19M |
| Enterprise Value | 60.47M | Income | -108.09M | Sales | 182.34K |
| Book/sh | -0.14 | Cash/sh | 0.95 | Dividend Yield | — |
| Payout | 0.00% | Employees | 134 | IPO | — |
| P/E | — | Forward P/E | -1.30 | PEG | — |
| P/S | 714.02 | P/B | -13.16 | P/C | — |
| EV/EBITDA | -0.69 | EV/Sales | 331.62 | Quick Ratio | 0.74 |
| Current Ratio | 0.79 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -2.72 | EPS next Y | -1.45 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-18 | ROA | -63.56% |
| ROE | -3.28% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -492.03% | Profit Margin | 0.00% | Shs Outstand | 68.70M |
| Shs Float | 53.35M | Short Float | 18.19% | Short Ratio | 8.10 |
| Short Interest | — | 52W High | 2.98 | 52W Low | 1.30 |
| Beta | 1.74 | Avg Volume | 1.44M | Volume | 542.33K |
| Target Price | $7.63 | Recom | None | Prev Close | $1.89 |
| Price | $1.90 | Change | 0.26% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$7.63
Mean price target
2. Current target
$1.90
Latest analyst target
3. DCF / Fair value
$-0.21
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.90
Low
$1.80
High
$13.00
Mean
$7.63
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-14 | reit | Piper Sandler | Overweight → Overweight | $6 |
| 2025-08-14 | reit | HC Wainwright & Co. | Neutral → Neutral | $3 |
| 2025-07-09 | init | Piper Sandler | — → Overweight | $5 |
| 2025-05-14 | reit | RBC Capital | Sector Perform → Sector Perform | $5 |
| 2025-05-14 | main | Oppenheimer | Outperform → Outperform | $13 |
| 2025-03-19 | main | RBC Capital | Sector Perform → Sector Perform | $5 |
| 2025-03-19 | reit | HC Wainwright & Co. | Neutral → Neutral | $3 |
| 2025-01-13 | main | HC Wainwright & Co. | Neutral → Neutral | $3 |
| 2025-01-10 | reit | JMP Securities | Market Outperform → Market Outperform | $18 |
| 2024-11-18 | main | HC Wainwright & Co. | Neutral → Neutral | $5 |
| 2024-11-18 | main | Oppenheimer | Outperform → Outperform | $15 |
| 2024-11-15 | main | RBC Capital | Sector Perform → Sector Perform | $6 |
| 2024-08-12 | main | Oppenheimer | Outperform → Outperform | $33 |
| 2024-08-09 | main | RBC Capital | Sector Perform → Sector Perform | $8 |
| 2024-07-15 | reit | HC Wainwright & Co. | Neutral → Neutral | $15 |
| 2024-05-14 | init | Stephens & Co. | — → Overweight | $20 |
| 2024-03-08 | main | Oppenheimer | Outperform → Outperform | $40 |
| 2024-03-07 | reit | RBC Capital | Sector Perform → Sector Perform | $11 |
| 2024-01-25 | up | Oppenheimer | Perform → Outperform | $4 |
News
RSS: Latest INO news- Is Inovio Pharmaceuticals Stock Going to $0? - The Motley Fool Mon, 23 Feb 2026 11
- INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire Fri, 20 Feb 2026 19
- INO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026 - PR Newswire Fri, 20 Feb 2026 14
- DNA medicine developer INOVIO to present research at four events - Stock Titan hu, 12 Feb 2026 08
- Trading (INO.UN) With Integrated Risk Controls (INO.UN:CA) - Stock Traders Daily Mon, 23 Feb 2026 16
- Inovio Pharmaceuticals: Speculative Buy Thesis Hinges On INO-3107 (NASDAQ:INO) - Seeking Alpha Sat, 10 Jan 2026 08
- Inovio Pharmaceuticals Securities Class Action Notice - Intellectia AI Sun, 22 Feb 2026 14
- Inovio (INO) Pops, Then Fades: Is This Biotech Rebound for Real? - AD HOC NEWS Sun, 22 Feb 2026 02
- INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights - PR Newswire Mon, 10 Nov 2025 08
- Biotech firm INOVIO gives new hire 24,000 stock options - Stock Titan Fri, 19 Dec 2025 08
- INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug - Yahoo Finance hu, 28 Aug 2025 07
- Inovio 3Q25 Review: EPS Miss, $25M Offering, And INO-3107 Progress (NASDAQ:INO) - Seeking Alpha Wed, 12 Nov 2025 08
- INOVIO Announces Proposed Public Offering - PR Newswire Mon, 10 Nov 2025 08
- INOVIO (NASDAQ: INO) completes rolling BLA for INO-3107 in RRP; priority review requested - Stock Titan Mon, 03 Nov 2025 08
- Leading DNA Medicine Developer INOVIO to Showcase Pipeline at Major Healthcare Investment Conference - Stock Titan Mon, 25 Aug 2025 07
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|
| 0 | 2916 | — | — | SUMNER MICHAEL JOHN | Officer | — | 2025-06-30 00:00:00 | D |
| 1 | 2167 | — | — | BENITO SIMON X | Director | — | 2025-05-21 00:00:00 | D |
| 2 | 2167 | — | — | SHEPARD JAY P. | Director | — | 2025-05-21 00:00:00 | D |
| 3 | 2167 | — | — | ZOTH LOTA S | Director | — | 2025-05-21 00:00:00 | D |
| 4 | 2167 | — | — | YARNO WENDY L | Director | — | 2025-05-21 00:00:00 | D |
| 5 | 2167 | — | — | WEINER DAVID B | Director | — | 2025-05-21 00:00:00 | D |
| 6 | 2167 | — | — | DANSEY ROGER D | Director | — | 2025-05-21 00:00:00 | D |
| 7 | 2167 | — | — | MILLER ANN CALBY M.D. | Director | — | 2025-05-21 00:00:00 | D |
| 8 | 4771 | — | — | KIES PETER D | Chief Financial Officer | — | 2025-05-15 00:00:00 | D |
| 9 | 4771 | — | — | HUMEAU LAURENT M | Officer | — | 2025-05-15 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -108.83M | -125.73M | -263.06M | -293.33M |
| TotalUnusualItems | 4.89M | -4.66M | -7.85M | -3.22M |
| TotalUnusualItemsExcludingGoodwill | 4.89M | -4.66M | -7.85M | -3.22M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -107.25M | -135.12M | -279.82M | -303.66M |
| ReconciledDepreciation | 3.13M | 3.50M | 5.50M | 4.73M |
| EBITDA | -103.95M | -130.39M | -270.90M | -296.56M |
| EBIT | -107.08M | -133.89M | -276.40M | -301.29M |
| NetInterestIncome | 4.59M | 6.91M | 3.53M | 1.43M |
| InterestExpense | 177.83K | 1.22M | 1.25M | 1.94M |
| InterestIncome | 4.77M | 8.13M | 4.78M | 3.36M |
| NormalizedIncome | -112.14M | -130.45M | -271.97M | -300.44M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -107.25M | -135.12M | -279.82M | -303.66M |
| TotalExpenses | 112.62M | 134.26M | 277.84M | 302.99M |
| TotalOperatingIncomeAsReported | -112.40M | -143.94M | -267.57M | -301.22M |
| DilutedAverageShares | 27.16M | 22.17M | 19.89M | 17.40M |
| BasicAverageShares | 27.16M | 22.17M | 19.89M | 17.40M |
| DilutedEPS | -3.95 | -6.09 | -14.04 | -17.45 |
| BasicEPS | -3.95 | -6.09 | -14.04 | -17.45 |
| DilutedNIAvailtoComStockholders | -107.25M | -135.12M | -279.82M | -303.66M |
| NetIncomeCommonStockholders | -107.25M | -135.12M | -279.82M | -303.66M |
| NetIncome | -107.25M | -135.12M | -279.82M | -303.66M |
| MinorityInterests | 0.00 | 0.00 | ||
| NetIncomeIncludingNoncontrollingInterests | -107.25M | -135.12M | -279.82M | -303.66M |
| NetIncomeContinuousOperations | -107.25M | -135.12M | -279.82M | -303.66M |
| EarningsFromEquityInterestNetOfTax | 0.00 | -2.17M | -434.39K | |
| TaxProvision | 0.00 | |||
| PretaxIncome | -107.25M | -135.12M | -277.65M | -303.22M |
| OtherIncomeExpense | 555.64K | -8.60M | -13.61M | -3.43M |
| OtherNonOperatingIncomeExpenses | -3.16M | -4.71M | -3.86M | 343.37K |
| SpecialIncomeCharges | 0.00 | -10.51M | 0.00 | 0.00 |
| ImpairmentOfCapitalAssets | 0.00 | 10.51M | 0.00 | 0.00 |
| EarningsFromEquityInterest | -1.17M | 773.14K | -1.90M | -553.57K |
| GainOnSaleOfSecurity | 4.89M | 5.85M | -7.85M | -3.22M |
| NetNonOperatingInterestIncomeExpense | 4.59M | 6.91M | 3.53M | 1.43M |
| InterestExpenseNonOperating | 177.83K | 1.22M | 1.25M | 1.94M |
| InterestIncomeNonOperating | 4.77M | 8.13M | 4.78M | 3.36M |
| OperatingIncome | -112.40M | -133.43M | -267.57M | -301.22M |
| OperatingExpense | 112.62M | 134.26M | 277.84M | 302.99M |
| ResearchAndDevelopment | 75.62M | 86.68M | 187.65M | 249.24M |
| SellingGeneralAndAdministration | 37.00M | 47.58M | 90.19M | 53.75M |
| GeneralAndAdministrativeExpense | 37.00M | 47.58M | 90.19M | 53.75M |
| OtherGandA | 37.00M | 47.58M | 90.19M | 53.75M |
| TotalRevenue | 217.76K | 832.01K | 10.26M | 1.77M |
| OperatingRevenue | 217.76K | 832.01K | 10.26M | 1.77M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| PreferredSharesNumber | 26.00 | 26.00 | 26.00 | 26.00 |
| OrdinarySharesNumber | 36.10M | 22.79M | 21.09M | 18.12M |
| ShareIssued | 36.10M | 22.79M | 21.09M | 18.12M |
| NetDebt | 2.46M | |||
| TotalDebt | 11.87M | 30.21M | 32.07M | 33.02M |
| TangibleBookValue | 68.50M | 117.35M | 209.72M | 386.53M |
| InvestedCapital | 68.50M | 134.12M | 238.98M | 414.63M |
| WorkingCapital | 62.50M | 110.54M | 218.37M | 382.70M |
| NetTangibleAssets | 68.50M | 117.35M | 209.72M | 386.53M |
| CapitalLeaseObligations | 11.87M | 13.44M | 15.46M | 18.06M |
| CommonStockEquity | 68.50M | 117.35M | 222.36M | 399.67M |
| TotalCapitalization | 68.50M | 117.35M | 238.98M | 414.63M |
| TotalEquityGrossMinorityInterest | 68.50M | 117.35M | 222.36M | 399.67M |
| StockholdersEquity | 68.50M | 117.35M | 222.36M | 399.67M |
| GainsLossesNotAffectingRetainedEarnings | -675.67K | -662.60K | -698.74K | -282.24K |
| OtherEquityAdjustments | -675.67K | -662.60K | -698.74K | -282.24K |
| RetainedEarnings | -1.73B | -1.62B | -1.49B | -1.21B |
| AdditionalPaidInCapital | 1.80B | 1.74B | 1.71B | 1.61B |
| CapitalStock | 36.10K | 22.79K | 21.09K | 217.38K |
| CommonStock | 36.10K | 22.79K | 21.09K | 217.38K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 44.69M | 53.60M | 126.17M | 96.27M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 9.37M | 11.03M | 29.30M | 30.53M |
| OtherNonCurrentLiabilities | 14.83K | |||
| NonCurrentDeferredLiabilities | 0.00 | 32.05K | 96.41K | |
| NonCurrentDeferredRevenue | 0.00 | 64.36K | ||
| NonCurrentDeferredTaxesLiabilities | 0.00 | 32.05K | 32.05K | |
| LongTermDebtAndCapitalLeaseObligation | 9.37M | 11.03M | 29.27M | 30.42M |
| LongTermCapitalLeaseObligation | 9.37M | 11.03M | 12.66M | 15.46M |
| LongTermDebt | 16.61M | 14.96M | ||
| CurrentLiabilities | 35.33M | 42.57M | 96.87M | 65.74M |
| OtherCurrentLiabilities | 13.26M | 109.41K | 2.56M | 4.60M |
| CurrentDeferredLiabilities | 0.00 | 21.63K | ||
| CurrentDeferredRevenue | 0.00 | 21.63K | ||
| CurrentDebtAndCapitalLeaseObligation | 2.50M | 19.18M | 2.80M | 2.60M |
| CurrentCapitalLeaseObligation | 2.50M | 2.41M | 2.80M | 2.60M |
| CurrentDebt | 16.77M | |||
| OtherCurrentBorrowings | 16.77M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 10.01M | 9.84M | 12.57M | 16.11M |
| PayablesAndAccruedExpenses | 9.57M | 13.45M | 78.93M | 42.41M |
| CurrentAccruedExpenses | 3.12M | 8.80M | 57.84M | 14.43M |
| Payables | 6.44M | 4.65M | 21.08M | 27.97M |
| AccountsPayable | 6.44M | 4.65M | 21.08M | 27.97M |
| TotalAssets | 113.20M | 170.95M | 348.53M | 495.94M |
| TotalNonCurrentAssets | 15.37M | 17.84M | 33.29M | 47.50M |
| OtherNonCurrentAssets | 1.98M | 605.32K | 684.04K | 1.43M |
| InvestmentsAndAdvances | 1.61M | 2.78M | 2.01M | 3.91M |
| LongTermEquityInvestment | 1.61M | 2.78M | 2.01M | 3.91M |
| InvestmentsinAssociatesatCost | 2.01M | 3.91M | ||
| InvestmentsinSubsidiariesatCost | 0.00 | |||
| GoodwillAndOtherIntangibleAssets | 0.00 | 12.64M | 13.14M | |
| OtherIntangibleAssets | 2.13M | 2.63M | ||
| Goodwill | 0.00 | 10.51M | 10.51M | |
| NetPPE | 11.77M | 14.45M | 17.96M | 29.02M |
| AccumulatedDepreciation | -16.46M | -20.85M | -21.56M | -18.94M |
| GrossPPE | 28.24M | 35.30M | 39.52M | 47.97M |
| Leases | 11.76M | 15.92M | 15.80M | 15.80M |
| OtherProperties | 10.95M | 13.03M | 15.53M | 23.96M |
| MachineryFurnitureEquipment | 5.53M | 6.36M | 8.19M | 8.20M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 97.83M | 153.11M | 315.24M | 448.44M |
| OtherCurrentAssets | 20.43K | 375.23K | 261.19K | |
| RestrictedCash | 0.00 | 30.00M | 0.00 | |
| PrepaidAssets | 2.52M | 5.41M | 20.13M | 38.84M |
| Receivables | 1.20M | 2.41M | 11.74M | 8.03M |
| DuefromRelatedPartiesCurrent | 1.20M | 2.41M | 10.04M | 2.57M |
| AccountsReceivable | 0.00 | 1.70M | 5.47M | |
| CashCashEquivalentsAndShortTermInvestments | 94.11M | 145.29M | 253.00M | 401.31M |
| OtherShortTermInvestments | 28.30M | 130.98M | 206.67M | 330.17M |
| CashAndCashEquivalents | 65.81M | 14.31M | 46.33M | 71.14M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -104.56M | -124.69M | -217.18M | -216.94M |
| RepaymentOfDebt | -16.41M | 0.00 | ||
| IssuanceOfDebt | 0.00 | 0.00 | ||
| IssuanceOfCapitalStock | 36.03M | 5.46M | 82.96M | 209.44M |
| CapitalExpenditure | -487.83K | -320.90K | -969.15K | -1.23M |
| InterestPaidSupplementalData | 533.49K | 1.07M | 1.07M | 1.08M |
| IncomeTaxPaidSupplementalData | 1.07M | 1.08M | ||
| EndCashPosition | 65.81M | 14.31M | 46.33M | 71.14M |
| BeginningCashPosition | 14.31M | 46.33M | 71.14M | 250.73M |
| EffectOfExchangeRateChanges | 32.40K | -3.92K | -25.56K | -30.13K |
| ChangesInCash | 51.47M | -32.01M | -24.79M | -179.55M |
| FinancingCashFlow | 51.48M | 5.00M | 81.84M | 211.50M |
| CashFlowFromContinuingFinancingActivities | 51.48M | 5.00M | 81.84M | 211.50M |
| NetOtherFinancingCharges | -420.80K | -466.65K | -1.40M | -4.61M |
| ProceedsFromStockOptionExercised | 32.28M | 0.00 | 283.02K | 6.67M |
| NetCommonStockIssuance | 36.03M | 5.46M | 82.96M | 209.44M |
| CommonStockIssuance | 36.03M | 5.46M | 82.96M | 209.44M |
| NetIssuancePaymentsOfDebt | -16.41M | 0.00 | 0.00 | 0.00 |
| NetShortTermDebtIssuance | -16.41M | 0.00 | ||
| ShortTermDebtPayments | -16.41M | 0.00 | ||
| NetLongTermDebtIssuance | 0.00 | 0.00 | ||
| LongTermDebtIssuance | 0.00 | 0.00 | ||
| InvestingCashFlow | 104.07M | 87.36M | 109.59M | -175.34M |
| CashFlowFromContinuingInvestingActivities | 104.07M | 87.36M | 109.59M | -175.34M |
| NetInvestmentPurchaseAndSale | 104.50M | 81.46M | 112.56M | -174.11M |
| SaleOfInvestment | 158.64M | 284.93M | 361.08M | 174.84M |
| PurchaseOfInvestment | -54.14M | -203.48M | -248.53M | -348.95M |
| NetBusinessPurchaseAndSale | 0.00 | -2.00M | 0.00 | |
| SaleOfBusiness | 0.00 | 0.00 | ||
| PurchaseOfBusiness | 0.00 | -2.00M | 0.00 | |
| NetPPEPurchaseAndSale | -428.51K | 5.90M | -969.15K | -1.23M |
| SaleOfPPE | 59.32K | 6.22M | 0.00 | 0.00 |
| PurchaseOfPPE | -487.83K | -320.90K | -969.15K | -1.23M |
| CapitalExpenditureReported | -1.23M | |||
| OperatingCashFlow | -104.08M | -124.37M | -216.22M | -215.71M |
| CashFlowFromContinuingOperatingActivities | -104.08M | -124.37M | -216.22M | -215.71M |
| ChangeInWorkingCapital | -2.66M | -10.26M | 19.83M | 50.35M |
| ChangeInOtherWorkingCapital | -1.57M | -2.02M | -2.69M | -2.37M |
| ChangeInOtherCurrentLiabilities | -109.41K | -2.45M | -2.05M | -3.02M |
| ChangeInOtherCurrentAssets | 38.90K | 78.73K | 741.75K | 24.53M |
| ChangeInPayablesAndAccruedExpense | -3.71M | -54.22M | 32.87M | 26.52M |
| ChangeInAccruedExpense | -343.52K | -8.23M | 267.81K | 375.92K |
| ChangeInPayable | -3.37M | -45.99M | 32.61M | 26.14M |
| ChangeInAccountPayable | -3.37M | -45.99M | 32.61M | 26.14M |
| ChangeInPrepaidAssets | 1.48M | 39.02M | -5.34M | -6.34M |
| ChangeInReceivables | 1.21M | 9.33M | -3.71M | 11.03M |
| ChangesInAccountReceivables | 1.21M | 9.33M | -3.71M | 11.03M |
| OtherNonCashItems | -355.65K | 155.81K | 186.98K | 858.64K |
| StockBasedCompensation | 6.60M | 11.07M | 22.56M | 26.34M |
| UnrealizedGainLossOnInvestmentSecurities | -2.08M | -5.85M | 7.85M | 3.05M |
| AssetImpairmentCharge | 0.00 | 12.50M | 0.00 | 0.00 |
| AmortizationOfSecurities | -1.69M | -4.69M | -1.32M | 1.63M |
| DeferredTax | 0.00 | -32.05K | 0.00 | 0.00 |
| DeferredIncomeTax | 0.00 | -32.05K | 0.00 | 0.00 |
| DepreciationAmortizationDepletion | 3.13M | 3.50M | 5.50M | 4.73M |
| DepreciationAndAmortization | 3.13M | 3.50M | 5.50M | 4.73M |
| AmortizationCashFlow | 0.00 | 145.42K | 496.49K | 520.41K |
| AmortizationOfIntangibles | 0.00 | 145.42K | 496.49K | 520.41K |
| Depreciation | 3.13M | 3.36M | 5.00M | 4.21M |
| OperatingGainsLosses | 240.74K | 4.35M | 9.00M | 993.35K |
| EarningsLossesFromEquityInvestments | 1.17M | -773.14K | 3.90M | 987.96K |
| GainLossOnInvestmentSecurities | -903.24K | 4.81M | 4.03M | 5.40K |
| NetForeignCurrencyExchangeGainLoss | -176.93K | |||
| GainLossOnSaleOfPPE | -22.47K | 318.00K | 1.07M | 0.00 |
| GainLossOnSaleOfBusiness | 0.00 | 0.00 | ||
| NetIncomeFromContinuingOperations | -107.25M | -135.12M | -279.82M | -303.66M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for INO
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|